Biologics Contract Development Market Size, Share & Trends Analysis Report By Source (Mammalian, Microbial), By Product Service Type, By Indication (Oncology, Immunological Disorders), By Region And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Biologics Contract Development Market Growth & Trends
The global biologics contract development market size is expected to reach USD 13.3 billion by 2030, according to a new report by Grand View Research, Inc, expanding at a CAGR of 10.5% from 2022 to 2030. The market comprises organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications, including drug screening, gene functional studies, and biologic production.
The market is segmented on the basis of biological source, product service (upstream and downstream), and indication. Factors such as the increasing adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries; and an increase in outsourcing of R&D activities are paving the way for the growth of the market. During the COVID-19 pandemic, a significant number of CROs partnered with biotechnology companies for R&D in COVID-19 vaccines. In 2022, there will be a significant number of companies undergoing research for a potential COVID-19 vaccine owing to the rising cases. This is expected to have a positive impact on the market.
Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and the amalgamation of advanced and specialized technologies. For instance, In September 2021, Curia Global, Inc., formerly AMRI, leading contract research, development, and manufacturing firm, acquired LakePharma Inc., a California-based biologics drug discovery, development, and manufacturing company. Many biopharma and pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development organization market growth in the coming years.
During the COVID-19 pandemic, the majority of clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to its rising incidence. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. According to the IQVIA report Oncology Trends 2022, the number of cancer clinical trials increased significantly in 2021. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.
Biologics Contract Development Market Report Highlights
Biologics Contract Development Market Growth & Trends
The global biologics contract development market size is expected to reach USD 13.3 billion by 2030, according to a new report by Grand View Research, Inc, expanding at a CAGR of 10.5% from 2022 to 2030. The market comprises organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications, including drug screening, gene functional studies, and biologic production.
The market is segmented on the basis of biological source, product service (upstream and downstream), and indication. Factors such as the increasing adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries; and an increase in outsourcing of R&D activities are paving the way for the growth of the market. During the COVID-19 pandemic, a significant number of CROs partnered with biotechnology companies for R&D in COVID-19 vaccines. In 2022, there will be a significant number of companies undergoing research for a potential COVID-19 vaccine owing to the rising cases. This is expected to have a positive impact on the market.
Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and the amalgamation of advanced and specialized technologies. For instance, In September 2021, Curia Global, Inc., formerly AMRI, leading contract research, development, and manufacturing firm, acquired LakePharma Inc., a California-based biologics drug discovery, development, and manufacturing company. Many biopharma and pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development organization market growth in the coming years.
During the COVID-19 pandemic, the majority of clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to its rising incidence. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. According to the IQVIA report Oncology Trends 2022, the number of cancer clinical trials increased significantly in 2021. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.
Biologics Contract Development Market Report Highlights
- Mammalian source emerged as the largest product segment in 2021, as the majority of research activities are being carried out using mammalian cell lines
- The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs)
- North America dominated the market in 2021. An increase in strategic acquisitions and partnerships and a rise in demand for specialized testing services are likely to have a positive impact on the market
- In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Source Type
1.1.2 Product Service Type
1.1.3 Disease Indication Type
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: Cagr Calculation
1.7 Model Details
1.7.1 Commodity Flow Analysis (Model 1)
1.7.2 Volume Price Analysis (Model 2)
1.7.2.1 Service Segment Analysis
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 List Of Secondary Sources
1.11 Objectives
1.11.1 Objective - 1:
1.11.2 Objective - 2:
1.11.3 Objective - 3:
1.11.4 Objective - 4:
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 BIOLOGICS CONTRACT DEVELOPMENT MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing Adoption Of Advanced Technologies
3.2.3 Increasing Mergers And Collaborations
3.2.4 Favorable Environment For Clinical Trials In Developing Countries
3.2.5 Increasing Outsourcing Of R&D Activities
3.2.6 Market Restraint Analysis
3.2.7 Intellectual Property Rights Issues
3.3 Penetration & Growth Prospect Mapping
3.4 Biologics Contract Development: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s Five Forces
3.4.2 Pestel Analysis
3.5 COVID-19 Impact On The Biologics Contract Development Market
CHAPTER 4 BIOLOGICS CONTRACT DEVELOPMENT MARKET: SOURCE TYPE SEGMENT ANALYSIS
4.1 Biologics Contract Development Market: Market Share Analysis, 2021 & 2030
4.1.1 Microbial
4.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
4.1.1.2 Mammalian
4.1.1.2.1 Mammalian Market, 2018 - 2030 (USD Million)
4.1.1.3 Others
4.1.1.3.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 BIOLOGICS CONTRACT DEVELOPMENT MARKET: PRODUCT SERVICE SEGMENT ANALYSIS
5.1 Biologics Contract Development Market: Market Share Analysis, 2021 & 2030
5.2 Cell Line Development
5.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.1 Microbial Cell Line Development
5.2.1.1.1 Microbial Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.2 Mammalian Cell Line Development
5.2.1.2.1 Mammalian Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.3 Others
5.2.1.3.1 Others Market, 2018 - 2030 (USD Million)
5.2.2 Process Development
5.2.2.1 Process Developmentmarket, 2018 - 2030 (USD Million)
5.2.2.2 Upstream Process Development
5.2.2.1.1 Upstream Process Development Market, 2018 - 2030 (USD Million)
5.2.2.1.1.1 Microbial
5.2.2.1.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
5.2.2.1.2.1 Mammalian
5.2.2.1.2.1.1 Mammalian Market, 2018 - 2030 (USD Million)
5.2.2.1.3.1 Others
5.2.2.1.3.1.1 Others Market, 2018 - 2030 (USD Million)
5.2.3 Downstream Process Development
5.2.3.1 Downstram Process Development, 2018 - 2030 (USD Million)
5.2.3.1.1 Impurity, Isolation, & Identification
5.2.3.1.1.1 Impurity, Isolation, & Identification Market, 2018 - 2030 (USD Million)
5.2.3.1.2 Physicochemical Characterization
5.2.3.1.2.1 Physicochemical Characterization Market, 2018 - 2030 (USD Million)
5.2.3.1.3 Pharmaceutical Analysis
5.2.3.1.3.1 Pharmaceutical Analysis Market, 2018 - 2030 (USD Million)
5.2.3.1.4 Others
5.2.3.1.4.1 Others Market, 2018 - 2030 (USD Million)
5.3.1 Downstream Process, By Product
5.3.1.1 Mabs (Monoclonal Antibodies)
5.3.1.1.1 Mabs (Monoclonal Antibodies) Market, 2018 - 2030 (USD Million)
5.3.1.2. Recombinant Proteins
5.3.1.2.1 Recombinant Proteins Analysis Market, 2018 - 2030 (USD Million)
5.3.1.3 Others
5.3.1.3.1 Others Market, 2018 - 2030 (USD Million)
5.4 Other Product Service (Quality And Regulatory Services, Etc)
5.4.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 6 BIOLOGICS CONTRACT DEVELOPMENT MARKET: INDICATION SEGMENT ANALYSIS
6.1 Biologics Contract Development Market: Market Share Analysis, 2021 & 2030
6.2 Oncology
6.2.1 Oncology Market, 2018 - 2030 (USD Million)
6.3 Immunological Disorders
6.3.1 Immunological Disorders Market, 2018 - 2030 (USD Million)
6.4 Cardiovascular Disorders
6.4.1 Cardiovascular Disorders Market, 2018 - 2030 (USD Million)
6.5 Hematological Disorders
6.5.1 Hematological Disorders Market, 2018 - 2030 (USD Million)
6.6 Others
6.6.1 others Market, 2018 - 2030 (USD Million)
CHAPTER 7 BIOLOGICS CONTRACT DEVELOPMENT MARKET: REGIONAL ANALYSIS
7.1 Biologics Contract Development: Regional Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.2 China
7.4.2.1 China Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.3 India
7.4.3.1 India Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.4 Japan
7.4.4.1 Japan Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.5 Colombia
7.5.5.1 Colobia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Biologics Contract Development Market, 2018 - 2030 (USD Million)
CHAPTER 8 COMPANY PROFILES
8.1 Compitative Landscape
8.2 Company Profile
8.2.1 Wuxi Biologics
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Service Benchmarking
8.2.1.4 Strategic Initiatives
8.2.2 Abzena Ltd
8.2.2.1 Company Overview
8.2.2.2 Service Benchmarking
8.2.2.3 Strategic Initiatives:
8.2.3 Fujifilm Diosynth Biotechnologies
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Service Benchmarking
8.2.3.4 Strategic Initiatives
8.2.4 Kbi Biopharma
8.2.4.1 Company Overview
8.2.4.2 Service Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Agc Biologics
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Service Benchmarking
8.2.5.4 Strategic Initiatives:
8.2.6 Thermo Fischer Scientific Inc.
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Service Benchmarking
8.2.6.4 Strategic Initiatives:
8.2.7 Curia Global, Inc
8.2.7.1 Company Overview
8.2.7.2 Service Benchmarking
8.2.7.3 Strategic Initiatives:
8.2.8 Genscript
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Service Benchmarking
8.2.8.4 Strategic Initiatives
8.2.9 Bionova Scientific Inc.
8.2.9.1 Company Overview
8.2.9.2 Service Benchmarking
8.2.10 Bioxcellence (Boehringer Ingelheim Biopharmaceuticals Gmbh)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Service Benchmarking
8.2.10.4 Strategic Initiatives:
8.2.11 Stc Biologics
8.2.11.1 Company Overview
8.2.11.2 Service Benchmarking
1.1 Market Segmentation & Scope
1.1.1 Source Type
1.1.2 Product Service Type
1.1.3 Disease Indication Type
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: Cagr Calculation
1.7 Model Details
1.7.1 Commodity Flow Analysis (Model 1)
1.7.2 Volume Price Analysis (Model 2)
1.7.2.1 Service Segment Analysis
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 List Of Secondary Sources
1.11 Objectives
1.11.1 Objective - 1:
1.11.2 Objective - 2:
1.11.3 Objective - 3:
1.11.4 Objective - 4:
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 BIOLOGICS CONTRACT DEVELOPMENT MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing Adoption Of Advanced Technologies
3.2.3 Increasing Mergers And Collaborations
3.2.4 Favorable Environment For Clinical Trials In Developing Countries
3.2.5 Increasing Outsourcing Of R&D Activities
3.2.6 Market Restraint Analysis
3.2.7 Intellectual Property Rights Issues
3.3 Penetration & Growth Prospect Mapping
3.4 Biologics Contract Development: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s Five Forces
3.4.2 Pestel Analysis
3.5 COVID-19 Impact On The Biologics Contract Development Market
CHAPTER 4 BIOLOGICS CONTRACT DEVELOPMENT MARKET: SOURCE TYPE SEGMENT ANALYSIS
4.1 Biologics Contract Development Market: Market Share Analysis, 2021 & 2030
4.1.1 Microbial
4.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
4.1.1.2 Mammalian
4.1.1.2.1 Mammalian Market, 2018 - 2030 (USD Million)
4.1.1.3 Others
4.1.1.3.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 BIOLOGICS CONTRACT DEVELOPMENT MARKET: PRODUCT SERVICE SEGMENT ANALYSIS
5.1 Biologics Contract Development Market: Market Share Analysis, 2021 & 2030
5.2 Cell Line Development
5.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.1 Microbial Cell Line Development
5.2.1.1.1 Microbial Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.2 Mammalian Cell Line Development
5.2.1.2.1 Mammalian Cell Line Development Market, 2018 - 2030 (USD Million)
5.2.1.3 Others
5.2.1.3.1 Others Market, 2018 - 2030 (USD Million)
5.2.2 Process Development
5.2.2.1 Process Developmentmarket, 2018 - 2030 (USD Million)
5.2.2.2 Upstream Process Development
5.2.2.1.1 Upstream Process Development Market, 2018 - 2030 (USD Million)
5.2.2.1.1.1 Microbial
5.2.2.1.1.1.1 Microbial Market, 2018 - 2030 (USD Million)
5.2.2.1.2.1 Mammalian
5.2.2.1.2.1.1 Mammalian Market, 2018 - 2030 (USD Million)
5.2.2.1.3.1 Others
5.2.2.1.3.1.1 Others Market, 2018 - 2030 (USD Million)
5.2.3 Downstream Process Development
5.2.3.1 Downstram Process Development, 2018 - 2030 (USD Million)
5.2.3.1.1 Impurity, Isolation, & Identification
5.2.3.1.1.1 Impurity, Isolation, & Identification Market, 2018 - 2030 (USD Million)
5.2.3.1.2 Physicochemical Characterization
5.2.3.1.2.1 Physicochemical Characterization Market, 2018 - 2030 (USD Million)
5.2.3.1.3 Pharmaceutical Analysis
5.2.3.1.3.1 Pharmaceutical Analysis Market, 2018 - 2030 (USD Million)
5.2.3.1.4 Others
5.2.3.1.4.1 Others Market, 2018 - 2030 (USD Million)
5.3.1 Downstream Process, By Product
5.3.1.1 Mabs (Monoclonal Antibodies)
5.3.1.1.1 Mabs (Monoclonal Antibodies) Market, 2018 - 2030 (USD Million)
5.3.1.2. Recombinant Proteins
5.3.1.2.1 Recombinant Proteins Analysis Market, 2018 - 2030 (USD Million)
5.3.1.3 Others
5.3.1.3.1 Others Market, 2018 - 2030 (USD Million)
5.4 Other Product Service (Quality And Regulatory Services, Etc)
5.4.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 6 BIOLOGICS CONTRACT DEVELOPMENT MARKET: INDICATION SEGMENT ANALYSIS
6.1 Biologics Contract Development Market: Market Share Analysis, 2021 & 2030
6.2 Oncology
6.2.1 Oncology Market, 2018 - 2030 (USD Million)
6.3 Immunological Disorders
6.3.1 Immunological Disorders Market, 2018 - 2030 (USD Million)
6.4 Cardiovascular Disorders
6.4.1 Cardiovascular Disorders Market, 2018 - 2030 (USD Million)
6.5 Hematological Disorders
6.5.1 Hematological Disorders Market, 2018 - 2030 (USD Million)
6.6 Others
6.6.1 others Market, 2018 - 2030 (USD Million)
CHAPTER 7 BIOLOGICS CONTRACT DEVELOPMENT MARKET: REGIONAL ANALYSIS
7.1 Biologics Contract Development: Regional Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.2 China
7.4.2.1 China Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.3 India
7.4.3.1 India Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.4 Japan
7.4.4.1 Japan Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.5.5 Colombia
7.5.5.1 Colobia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Biologics Contract Development Market, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Biologics Contract Development Market, 2018 - 2030 (USD Million)
CHAPTER 8 COMPANY PROFILES
8.1 Compitative Landscape
8.2 Company Profile
8.2.1 Wuxi Biologics
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Service Benchmarking
8.2.1.4 Strategic Initiatives
8.2.2 Abzena Ltd
8.2.2.1 Company Overview
8.2.2.2 Service Benchmarking
8.2.2.3 Strategic Initiatives:
8.2.3 Fujifilm Diosynth Biotechnologies
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Service Benchmarking
8.2.3.4 Strategic Initiatives
8.2.4 Kbi Biopharma
8.2.4.1 Company Overview
8.2.4.2 Service Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Agc Biologics
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Service Benchmarking
8.2.5.4 Strategic Initiatives:
8.2.6 Thermo Fischer Scientific Inc.
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Service Benchmarking
8.2.6.4 Strategic Initiatives:
8.2.7 Curia Global, Inc
8.2.7.1 Company Overview
8.2.7.2 Service Benchmarking
8.2.7.3 Strategic Initiatives:
8.2.8 Genscript
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Service Benchmarking
8.2.8.4 Strategic Initiatives
8.2.9 Bionova Scientific Inc.
8.2.9.1 Company Overview
8.2.9.2 Service Benchmarking
8.2.10 Bioxcellence (Boehringer Ingelheim Biopharmaceuticals Gmbh)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Service Benchmarking
8.2.10.4 Strategic Initiatives:
8.2.11 Stc Biologics
8.2.11.1 Company Overview
8.2.11.2 Service Benchmarking
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 1 List of secondary sources
Table 2 List of Abbreviations
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Biologics Contract Development market snapshot (2021)
Fig. 11 Biologics Contract Development market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Biologics Contract Development market product type outlook: Segment dashboard
Fig. 18 Biologics Contract Development market: product movement analysis
Fig. 19 Microbial market, 2018 - 2030 (USD Million)
Fig. 20 Mammalian market, 2018 - 2030 (USD Million)
Fig. 21 Others market, 2018 - 2030 (USD Million)
Fig. 22 Biologics Contract Development market product service outlook: Segment dashboard
Fig. 23 Biologics Contract Development market: product movement analysis
Fig. 24 Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 25 Microbial Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 26 Mammalian Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 27 Others market, 2018 - 2030 (USD Million)
Fig. 28 Process development market, 2018 - 2030 (USD Million)
Fig. 29 Upstream Process Development market, 2018 - 2030 (USD Million)
Fig. 30 Microbial market, 2018 - 2030 (USD Million)
Fig. 31 Mammalian market, 2018 - 2030 (USD Million)
Fig. 32 Others market, 2018 - 2030 (USD Million)
Fig. 33 Downstream Process Development market, 2018 - 2030 (USD Million)
Fig. 34 Impurity, isolation, & identification market, 2018 - 2030 (USD Million)
Fig. 35 Physicochemical characterization market, 2018 - 2030 (USD Million)
Fig. 36 Pharmaceutical analysis market, 2018 - 2030 (USD Million)
Fig. 37 Others market, 2018 - 2030 (USD Million)
Fig. 38 MABS (Monoclonal Antibodies) market, 2018 - 2030 (USD Million)
Fig. 39 Recombinant proteins market, 2018 - 2030 (USD Million)
Fig. 40 Others market, 2018 - 2030 (USD Million)
Fig. 41 Others market, 2018 - 2030 (USD Million)
Fig. 42 Biologics Contract Development market indication outlook: Segment dashboard
Fig. 43 Biologics Contract Development market: indication movement analysis
Fig. 44 Oncology market, 2018 - 2030 (USD Million)
Fig. 45 Immunological disorders market, 2018 - 2030 (USD Million)
Fig. 46 Cardiovascular disorders market, 2018 - 2030 (USD Million)
Fig. 47 Hematological disorders market, 2018 - 2030 (USD Million)
Fig. 48 Others market, 2018 - 2030 (USD Million)
Fig. 49 Regional market: Key takeaways
Fig. 50 Regional outlook, 2021 & 2030
Fig. 51 North America market, 2018 - 2030 (USD Million)
Fig. 52 U.S. market, 2018 - 2030 (USD Million)
Fig. 53 Canada market, 2018 - 2030 (USD Million)
Fig. 54 Europe market, 2018 - 2030 (USD Million)
Fig. 55 U.K. market, 2018 - 2030 (USD Million)
Fig. 56 Germany market, 2018 - 2030 (USD Million)
Fig. 57 France market, 2018 - 2030 (USD Million)
Fig. 58 Italy market, 2018 - 2030 (USD Million)
Fig. 59 Spain market, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 61 China market, 2018 - 2030 (USD Million)
Fig. 62 India market, 2018 - 2030 (USD Million)
Fig. 63 Japan market, 2018 - 2030 (USD Million)
Fig. 64 Australia market, 2018 - 2030 (USD Million)
Fig. 65 South Korea market, 2018 - 2030 (USD Million)
Fig. 66 Latin America market, 2018 - 2030 (USD Million)
Fig. 67 Brazil market, 2018 - 2030 (USD Million)
Fig. 68 Mexico market, 2018 - 2030 (USD Million)
Fig. 69 Argentina market, 2018 - 2030 (USD Million)
Fig. 70 Colombia market, 2018 - 2030 (USD Million)
Fig. 71 MEA market, 2018 - 2030 (USD Million)
Fig. 72 South Africa market, 2018 - 2030 (USD Million)
Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 74 UAE market, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Biologics Contract Development market snapshot (2021)
Fig. 11 Biologics Contract Development market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Biologics Contract Development market product type outlook: Segment dashboard
Fig. 18 Biologics Contract Development market: product movement analysis
Fig. 19 Microbial market, 2018 - 2030 (USD Million)
Fig. 20 Mammalian market, 2018 - 2030 (USD Million)
Fig. 21 Others market, 2018 - 2030 (USD Million)
Fig. 22 Biologics Contract Development market product service outlook: Segment dashboard
Fig. 23 Biologics Contract Development market: product movement analysis
Fig. 24 Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 25 Microbial Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 26 Mammalian Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 27 Others market, 2018 - 2030 (USD Million)
Fig. 28 Process development market, 2018 - 2030 (USD Million)
Fig. 29 Upstream Process Development market, 2018 - 2030 (USD Million)
Fig. 30 Microbial market, 2018 - 2030 (USD Million)
Fig. 31 Mammalian market, 2018 - 2030 (USD Million)
Fig. 32 Others market, 2018 - 2030 (USD Million)
Fig. 33 Downstream Process Development market, 2018 - 2030 (USD Million)
Fig. 34 Impurity, isolation, & identification market, 2018 - 2030 (USD Million)
Fig. 35 Physicochemical characterization market, 2018 - 2030 (USD Million)
Fig. 36 Pharmaceutical analysis market, 2018 - 2030 (USD Million)
Fig. 37 Others market, 2018 - 2030 (USD Million)
Fig. 38 MABS (Monoclonal Antibodies) market, 2018 - 2030 (USD Million)
Fig. 39 Recombinant proteins market, 2018 - 2030 (USD Million)
Fig. 40 Others market, 2018 - 2030 (USD Million)
Fig. 41 Others market, 2018 - 2030 (USD Million)
Fig. 42 Biologics Contract Development market indication outlook: Segment dashboard
Fig. 43 Biologics Contract Development market: indication movement analysis
Fig. 44 Oncology market, 2018 - 2030 (USD Million)
Fig. 45 Immunological disorders market, 2018 - 2030 (USD Million)
Fig. 46 Cardiovascular disorders market, 2018 - 2030 (USD Million)
Fig. 47 Hematological disorders market, 2018 - 2030 (USD Million)
Fig. 48 Others market, 2018 - 2030 (USD Million)
Fig. 49 Regional market: Key takeaways
Fig. 50 Regional outlook, 2021 & 2030
Fig. 51 North America market, 2018 - 2030 (USD Million)
Fig. 52 U.S. market, 2018 - 2030 (USD Million)
Fig. 53 Canada market, 2018 - 2030 (USD Million)
Fig. 54 Europe market, 2018 - 2030 (USD Million)
Fig. 55 U.K. market, 2018 - 2030 (USD Million)
Fig. 56 Germany market, 2018 - 2030 (USD Million)
Fig. 57 France market, 2018 - 2030 (USD Million)
Fig. 58 Italy market, 2018 - 2030 (USD Million)
Fig. 59 Spain market, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 61 China market, 2018 - 2030 (USD Million)
Fig. 62 India market, 2018 - 2030 (USD Million)
Fig. 63 Japan market, 2018 - 2030 (USD Million)
Fig. 64 Australia market, 2018 - 2030 (USD Million)
Fig. 65 South Korea market, 2018 - 2030 (USD Million)
Fig. 66 Latin America market, 2018 - 2030 (USD Million)
Fig. 67 Brazil market, 2018 - 2030 (USD Million)
Fig. 68 Mexico market, 2018 - 2030 (USD Million)
Fig. 69 Argentina market, 2018 - 2030 (USD Million)
Fig. 70 Colombia market, 2018 - 2030 (USD Million)
Fig. 71 MEA market, 2018 - 2030 (USD Million)
Fig. 72 South Africa market, 2018 - 2030 (USD Million)
Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 74 UAE market, 2018 - 2030 (USD Million)
